Position in ANAB
as of Jun 30, 2026
· filed Aug 10, 2026
Position Value
$615,195
-$426,065 QoQ
Shares Held
9,114
-67.6% QoQ
Ownership
0.031%
of shares outstanding
% of Portfolio
0.17%
of 13F equity value
Holder Rank
#112
of 213 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ANAB Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026DCF Advisers, LLC holds $72,469,035 across 22 Biotechnology names. ANAB ranks #19 (0.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ARGX |
Argenx SE
|
14,200 | $13,174,334 | |
| 2 | CRVS |
Corvus Pharmaceuticals, Inc.
|
637,500 | $9,524,250 | |
| 3 | HELP |
Cybin Inc.
|
1,434,988 | $9,485,270 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
9,250 | $5,767,745 | |
| 5 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
11,500 | $5,712,395 | |
| 6 | NAMS |
NewAmsterdam Pharma Co N.V.
|
141,000 | $4,778,490 | |
| 7 | INCY |
Incyte Corp
|
41,500 | $4,704,440 | |
| 8 | IMRX |
Immuneering Corp
|
790,000 | $3,942,100 |
All Filings in ANAB
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $615,195 | 9,114 | Shares | Sole | 2026-08-10 | |
| 2026-03-31 | $1,041,260 | 18,775 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $1,708,920 | 35,250 | Shares | Sole | 2026-02-11 | |
| 2025-09-30 | $1,469,757 | 48,000 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $1,065,600 | 48,000 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $647,859 | 34,850 | Shares | Sole | 2025-05-09 | |
| No filing history on record for this holder in this stock. | ||||||